InflaRx (IFRX) EBITDA Margin (QoQ) (2018 - 2026)
InflaRx (IFRX) EBITDA Margin (QoQ) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.08 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.11 Bn | 78.11 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn |
| 4 | Moderna | 56.09 Bn | 50.96 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.49 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37,694.00 |
| Dec 31, 2025 | 3.98 Mn |
| Sep 30, 2025 | -700,905.00 |
| Jun 30, 2025 | 332,813.00 |
| Mar 31, 2025 | -3.62 Mn |
| Dec 31, 2024 | 1.25 Mn |
| Sep 30, 2024 | 22.98 Mn |
| Jun 30, 2024 | -20.75 Mn |
| Mar 31, 2024 | -3.46 Mn |
| Dec 31, 2023 | -2,965.00 |
| Sep 30, 2023 | -59,315.00 |
| Jun 30, 2023 | 59,313.00 |
| Mar 31, 2023 | 231,411.00 |
| Dec 31, 2022 | -360,509.00 |
| Sep 30, 2022 | 129,829.00 |
| Jun 30, 2022 | -179,267.00 |
| Mar 31, 2022 | 178,516.00 |
| Dec 31, 2021 | -190,552.00 |
| Sep 30, 2021 | 200,572.00 |
| Jun 30, 2021 | -54,129.00 |